Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease

Shah, Nisha B.; Zuckerman, Autumn D.; Hosteng, Katie R.; Fann, Jessica; DeClercq, Josh; Choi, Leena; Cherry, Laura; Schwartz, David A.; Horst, Sara

doi:10.1007/s10620-023-08098-7

Dig Dis Sci

2023

DOI: 10.1007/s10620-023-08098-7

|View full text |Cite

Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease

Nisha B. Shah,

Autumn D. Zuckerman,

Katie R. Hosteng

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2025

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance?

Constant,

Scott

2023

Dig Dis Sci

View full text Add to dashboard Cite

The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance?

Constant,

Scott

2023

Dig Dis Sci

View full text Add to dashboard Cite

Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning

Fudman,

McConnell,

et al. 2024

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Implementing a letter template to expedite specialty medication appeal letter submission

Fann,

Kozlicki,

Whelchel

2025

Journal of the American Pharmacists Association

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease

Cited by 6 publications

References 41 publications

The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance?

The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance?

Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning

Implementing a letter template to expedite specialty medication appeal letter submission

Contact Info

Product

Resources

About